Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Reach Market Services Meet the CEO (October 2020)
18 slides from Amplia Therapeutics's conference presentation, Oct 21, 2020
Slide 1: Amplia Presents at Reach Market Services Meet the CEO
ABN 16 165 160 841 ASX RELEASE 21st October 2020 For personal use only Amplia Presents at Reach Market Services “Meet the CEO” Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to provide the CEO’s Presentation which will be made today at 12 p.m. AEDT via a live webinar h
Slide 2: Amplia Therapeutics
For personal use only Amplia Therapeutics October 2020 Amplia Therapeutics Limited
Slide 3: Disclaimer
Disclaimer For personal use only The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is mad
Slide 4: Company highlights
Company highlights For personal use only Developing small molecule drugs for two, significant disease areas: • cancer – combo therapy in hard-to-treat solid tumours • fibrosis – prevention and treatment Range of commercial opportunities for partnering, licensing and co-development First Phase 1 clin
Slide 5: Amplia's FAKi's provide a promising opportunity set
Amplia’s FAKi’s provide a promising opportunity set For personal use only Amplia is developing Amplia’s experimental drug candidates offer several commercial opportunities Amplia is taking three approaches to realize these opportunities: 1. Clinical development for pancreatic cancer and idiopathic l
Slide 6: Company snapshot
Company snapshot1 For personal use only Shares 107.4M ATX Price and Volume – 12 months Market cap $29.0M Options 14.1M Cash 2 $4.0M Last qtr burn 3 ($0.4M) Listed May 2018 Headquarters Melbourne Board Warwick Tong (Chair) John Lambert (MD) Robert Peach (NED) Chris Burns (NED) Substantial institution
Slide 7: Achievements to date in 2020
Achievements to date in 2020 For personal use only • Jan 2020 – Placement raising $930K at $0.07/share corner-stoned by Platinum • Jan 2020 – Completed restructure and streamlining of Board • Feb 2020 – Paul Timpson joins Scientific Advisory Board • Mar 2020 – Orphan Drug Designation awarded for pan
Slide 8: Cancer Treatments
For personal use only Cancer Treatments
Slide 9: Why cancer drugs often do not work
Why cancer drugs often do not work For personal use only Pharmaceutical strategies to treat cancer: 1. cytotoxic drugs: target rapidly dividing cancer cells 2. targeted drugs: block specific proteins elevated in cancer cells 3. anti-angiogenic drugs: block new blood vessels which feed the cancer 4.
Slide 10: Amplia's drugs target cancer defence mechanisms
Amplia’s drugs target cancer defence mechanisms For personal use only Fibrosis • elevated levels of FAK in cancers are FAK helps establish and associated with poor outcomes maintain the dense, fibrotic tissue around cancers • increased FAK activity is found in many difficult-to-treat, solid cancers
Slide 11: AMP945 – treatment of solid cancers
AMP945 – treatment of solid cancers For personal use only Pancreatic cancer • FDA Orphan Drug Designation for AMP945 in the treatment of pancreatic cancer received in March 2020 • Collaboration with Prof. Paul Timpson at the Garvan Institute to assess novel combination therapies for pancreatic cance
Slide 12: Fibrosis Treatments
For personal use only Fibrosis Treatments
Slide 13: FAK in Idiopathic Pulmonary Fibrosis
FAK in Idiopathic Pulmonary Fibrosis For personal use only Idiopathic Pulmonary Fibrosis (IPF) is a devastating, progressive disease caused by the build-up of fibrotic tissue in the lung which affects 3M people worldwide, including 130,000 in the US • Left untreated, the median survival time is 2-3
Slide 14: Potential for anti-fibrotic therapy beyond IPF
Potential for anti-fibrotic therapy beyond IPF For personal use only Microbial respiratory infections Many bacterial and viral infections damage lung tissue or induce an inflammatory responses that results in scarring and fibrosis which can have long term impacts on respiratory function Silicosis Si
Slide 15: Status and Outlook
For personal use only Status and Outlook
Slide 16: Phase 1 Trial of AMP945
Phase 1 Trial of AMP945 For personal use only First clinical trial of AMP945 commenced dosing in October 2020 Phase 1 safety trial of orally administered AMP945 in healthy volunteers: • Single Australian site • 64 volunteers, cost of ~$2M • Single ascending dose (SAD) and multiple ascending dose (MA
Slide 17: Upcoming targeted milestones
Upcoming targeted milestones For personal use only • Nov 2020 – Significant research collaboration • Dec 2020 – Start dosing of multi-dose arm of Phase 1 clinical trial • Q2 2021 - Selection of first indication for Phase 2 based on preclinical combo studies • Q2 2021 - Headline data from Phase 1 cli
Slide 18: ampliatx.com
For personal use only ampliatx.com
Amplia Therapeutics — Reach Market Services Meet the CEO (October 2020) on 6ix